Macrophages: A Key Population for the Resistance Acquisition in BRAF Mutant Melanoma

Macrophages: A Key Population for the Resistance Acquisition in BRAF Mutant Melanoma

Saved in:

Bibliographic Details
Main Authors:	P. Sisó Camarasa, I. de la Rosa Zurera, C. Ríos Martínez, O. Maiques Carlos, C. Barceló Gomez, X. Soria Gili, X. Matias-Guiu Guia, A. Macià Armengol, R.M. Marti
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	EJC Skin Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772611824001186
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Targeting autophagy as a therapeutic intervention in BRAFV600E melanoma cells through ULK-1 inhibition
by: C. Ríos Martínez, et al.
Published: (2024-01-01)

Braf-Mutant Melanomas: Biology and Therapy
by: Elvira Pelosi, et al.
Published: (2024-12-01)

Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma
by: Josué Ballesteros-Álvarez, et al.
Published: (2024-10-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
by: Eva Marie Erfurth, et al.
Published: (2024-12-01)

BRAF-mutant melanoma management: a single center retrospective analysis of patients treated with sequential therapy
by: Ilaria Proietti, et al.
Published: (2024-12-01)

BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy
by: Vinay K. Pattalachinti, et al.
Published: (2025-02-01)

Dihydrotanshinone I enhanced BRAF mutant melanoma treatment efficacy by inhibiting the STAT3/SOX2 signaling pathway
by: Xing Luo, et al.
Published: (2025-01-01)

Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment
by: Sara Marchisio, et al.
Published: (2024-11-01)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
by: Yasar Subutay Peker, et al.
Published: (2018-01-01)

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
by: Antoni Ribas, et al.
Published: (2020-10-01)

Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
by: Khin Thway, et al.
Published: (2020-10-01)

Magnolol induces cell death through PI3K/Akt‐mediated epigenetic modifications boosting treatment of BRAF‐ and NRAS‐mutant melanoma
by: Abdullah Al Emran, et al.
Published: (2019-03-01)

Melanoma genomics – will we go beyond BRAF in clinics?
by: Justyna Mirek, et al.
Published: (2024-09-01)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation
by: Yu. S. Shakh-Paronyants, et al.
Published: (2023-03-01)

Electronic patient-reported outcomes, fever management, and symptom prediction among patients with BRAF V600 mutant stage III–IV melanoma: The Kaiku Health platform
by: Peter Mohr, et al.
Published: (2024-12-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

Fulminant Disseminated Intravascular Coagulation as Initial Presentation of BRAF-Mutated Melanoma
by: Jeremy Chuang, et al.
Published: (2019-01-01)

Role of eIF6 in Modulating Response to BRAF Inhibitors and Acquired Resistance in Cutaneous Melanoma
by: G. Kyriakopoulos, et al.
Published: (2024-01-01)

Predicting BRAF Mutations in Cutaneous Melanoma Patients Using Neural Network Analysis
by: Oleksandr Dudin, et al.
Published: (2024-01-01)

Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma
by: Brenen P. Swofford, et al.
Published: (2017-01-01)

Circulating tumor DNA: a promising biomarker in stage III BRAF+ melanoma
by: G. Roccuzzo, et al.
Published: (2024-01-01)

Adjuvant therapy for Asian patients with resected stage III/IV BRAF V600-mutant melanoma with more than 3 years of follow-up: A multicenter retrospective study in Japan
by: K. Namikawa, et al.
Published: (2024-01-01)

A Case Presentation of a Patient with Microsatellite Instability and BRAF Mutant Metastatic Colon Cancer and Bibliography Update
by: K. Thomopoulou, et al.
Published: (2019-01-01)

BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab
by: Toru Imai, et al.
Published: (2024-12-01)

Patient treatment preferences in unresectable/metastatic BRAF-mutated melanoma: a qualitative study
by: T. Amaral, et al.
Published: (2024-01-01)

Pharmacokinetic Evaluation of [C]CEP-32496 in Nude Mice Bearing BRAF Mutation-Induced Melanomas
by: Cuiping Jiang MMSc, et al.
Published: (2018-09-01)

Global trends and emerging insights in BRAF and MEK inhibitor resistance in melanoma: a bibliometric analysis
by: Jianhao Bai, et al.
Published: (2025-01-01)

SILAC-based quantification reveals modulation of the immunopeptidome in BRAF and MEK inhibitor sensitive and resistant melanoma cells
by: Melissa Bernhardt, et al.
Published: (2025-01-01)

The Olive Oil Monophenolic Secoiridoid Ligstroside Aglycone Suppresses Melanoma Progression by Targeting the BRAF Signaling Pathway
by: Md Ashiq Mahmud, et al.
Published: (2025-01-01)

Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma
by: Ian F Hermans, et al.
Published: (2024-04-01)

CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
by: Victoria Jennings, et al.
Published: (2022-03-01)

Real-world effectiveness of dabrafenib and trametinib in patients with BRAF-positive melanoma treated in routine Bulgarian clinical practice
by: Alexandra Savova, et al.
Published: (2024-12-01)

20918. CONVERSIÓN ENTRE ROWLAND UNIVERSAL DEMENTIA ASSESSMENT SCALE (RUDAS) Y TEST MINIMENTAL STATE EXAMINATION (MMSE) EN POBLACIONES MAYORITARIAS Y MINORITARIAS
by: C. Delgado Alonso, et al.
Published: (2024-11-01)

Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation
by: K. Sahadudheen, et al.
Published: (2016-01-01)

Loss of Lkb1 cooperates with BrafV600E and ultraviolet radiation, increasing melanoma multiplicity and neural‐like dedifferentiation
by: Kimberley McGrail, et al.
Published: (2025-02-01)

RIPK4 Downregulation Reduces ABCG2 Expression, Increasing BRAF-Mutated Melanoma Cell Susceptibility to Cisplatin- and Doxorubicin-Induced Apoptosis
by: Bartlomiej Olajossy, et al.
Published: (2024-12-01)

Second-generation BRAF inhibitor Encorafenib resistance is regulated by NCOA4-mediated iron trafficking in the drug-resistant malignant melanoma cells
by: Ceyda Colakoglu Bergel, et al.
Published: (2025-01-01)

The RoMEO study: a real-world, observational, prospective investigation of dabrafenib and trametinib combination treatment in patients with BRAF V600 unresectable or metastatic cutaneous melanoma
by: L. Mortier, et al.
Published: (2024-01-01)

Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial
by: David Malka, et al.
Published: (2022-11-01)

Correction: The landscape of BRAF transcript and protein variants in human cancer
by: Andrea Marranci, et al.
Published: (2025-02-01)